One… uh, Two Small Steps for Pharmaco Blogging!
Recently, two pharmaceutical company blogs have officially entered the Pharma Blogosphere: Johnson & Johnson's JNJ BTW and Glaxo's alliConnect.
Moore: Please Don’t Ignore Us Pharma Bloggers
Mr. Moore, please invite to a private screening of your movie SiCKO just like Centocor invited me to a private screening of it's movie InnerState.
Measuring an Intangible: Medical Science Liaison Metrics Consensus
This article by Dr. Jane Chin of the Medical Science Liaison Institute, offers suggestions for MSL metrics based on results of a consensus survey.
Optimizing Brand Equity: Pre-Launch through Patent Expiry and Beyond!
There are few new blockbusters on the horizon and many profitable drugs are coming off patent. If pharmaceutical marketers want seats at the table, then they must show how marketing can contribute to long-term company financial performance.
Mobile Pharma Marketing: What’s the 411?
Mobile devices -- especially cell phones -- are becoming ubiquitous in the U.S. How can pharmaceutical companies use this technology for consumer acquisition and retention? To get some ideas, we interviewed Robert Flynn, President of Pulse Media Response, LLC, and summarize that discussion in this article.
Murky Physician Marketing and Education Practices
This commentary takes a look at some
Full Disclosure
I will be attending J&J's Las Vegas reception
How Readable, Credible & Useful are Pharma Blogs?
This article presents the compllete results from the first ever survey of The Pharma Blogosphere in which blog readers evaluate 22 different pharma-related blogs on the basis of readability, credibility, usefulness, and bias.
Targeted Faith-based Disease Awareness Marketing
This article describes a new health awareness initiative intended to reach African Americans via churches and health ministries.
Americans Skeptical of Pharma Cause Marketing
A new survey by Envision Solutions, LLC, a healthcare marketing communications company, suggests that many Americans are deeply skeptical of pharmaceutical companies' motives for supporting non-profit patient advocacy groups.
